Commentary to“Carrimycin,a first in-class anti-cancer agent,targets selenoprotein H to induce nucleolar oxidative stress and inhibit ribosomal biogenesis”  

作　　者：Peng Lyu 

机构地区：[1]Cancer Pathogenisis and Therapy,Chinese Medical Association Publishing House,Beijing 100052,China [2]Key Laboratory of Knowledge Mining and Service for Medical Journals,National Press and Publication Administration,Beijing 100052,China

出　　处：《Cancer Pathogenesis and Therapy》2023年第2期157-158,共2页癌症发生与治疗（英文）

摘　　要：On January 2,2023,Cancer Pathogenesis and Therapy(CPT)published an online article entitled“Carrimycin as an anticancer candidate inhibits tumors by targeting selenoprotein H in the nucleus of tumor cells to induce nuclear oxidative stress and inhibit ribosome biosynthesis,”authored by Yu LC et al.1 from the National Cancer Institute of the National Institutes of Health.Yu LC et al.1 discovered that isovalerylspiramycin I(ISP I)—the key active ingredient of carrimycin2—directly inhibits selenoprotein H(SELH)expression.As the sole antioxidant enzyme in the nucleolus,SELH serves key regulatory roles in relation to numerous oxidants produced during rapid rRNA synthesis.

关 键 词：expression. al. Cancer 

分 类 号：R730.2[医药卫生—肿瘤]